ONO-4538 Phase I Study - A Single Center, Open Label, Dose Escalation Single Dose, Followed by Multiple Dose Study of ONO-4538, a Fully Human mAb to PD-1, in Patients With Advanced Malignant Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 08 Dec 2016 Results published in the Investigational New Drugs
- 24 Nov 2016 Status changed from active, no longer recruiting to completed.
- 27 Jun 2011 Planned end date changed from 1 May 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.